医学
优势比
改良兰金量表
置信区间
冲程(发动机)
内科学
肌酐
心脏病学
脑梗塞
缺血性中风
入射(几何)
死亡率
样本量测定
不利影响
脑出血
荟萃分析
血清尿素
诊断优势比
重症监护医学
外科
心肌梗塞
作者
Sana Aftabi Yousefabad,Rasa Beheshti,Seyyed Sina Hejazian,Afshin Moaradi,Asal Ebrahimian,Ramin Zand
标识
DOI:10.1093/esj/aakag023.1290
摘要
Abstract Background and aims This study aims to summarize and evaluate the evidence assessing the association of parameters of poor outcomes in ischemic stroke patients undergoing endovascular thrombectomy (EVT) with the urea to creatinine (BUN/Cr) ratio at admission Methods PubMed, Web of science, and Embase, were searched from the inception to July 2025. Studies assessing the association between elevated admission BUN/Cr ratio and poor outcomes in ischemic stroke patients undergoing EVT were included. Poor outcomes comprised failed recanalization (thrombolysis in cerebral infarction score ≥ 2a), symptomatic hemorrhagic transformation (≥4-point National Institutes of Health Stroke Scale increase), unfavorable functional outcome (modified Rankin score 3-5), and all-cause mortality. Non-English papers, case reports, reviews, letters, commentaries, and conference abstracts were excluded. Risk of bias of finally included studies was assessed by the QUIPS tool. Data of adjusted Odds ratio (aOR) for multivariable analysis with 95% confidence interval (CI) were pooled in the meta-analysis. Results After screening for eligible studies, 2 articles with total sample size of 436 patients were included. Predefined BUN/Cr cut offs were 15 and 22. Elevated BUN/CR ratio above mentioned levels were statistically associated with more level of insufficient recanalization (aOR: 1.29, CI: 1.03-1.60), more rates of symptomatic hemorrhagic transformation (aOR: 1.48, CI: 1.19-1.84), more rates of unfavorable outcomes (aOR: 1.61, CI: 1.34-1.93), and more rates of mortality (aOR: 1.61, CI: 1.34-1.93). Our findings encourage fluid therapy to reduce dehydration as the most common causes of rise of BUN/Cr before EVT. Conflict of interest sana aftabi: Nothing to disclose
科研通智能强力驱动
Strongly Powered by AbleSci AI